- Details
- Zach Klaassen engages with Talal El Zarif and Karl Semaan to discuss the results of the KEYNOTE-564 trial on adjuvant immunotherapy for renal cell carcinoma (RCC). The conversation emphasizes the landmark approval of pembrolizumab as adjuvant therapy in early-stage RCC, highlighting a significant shift in treatment paradigms where adjuvant systemic therapy had been absent for over fifty years. Drs...
|
- Details
- Phillip Koo interviews Shankar Siva about advancements in functional renal imaging. Dr. Siva discusses the current standard imaging for localized kidney cancer, which includes triple-phase CT or MRI with IV contrast, and the limitations of bone scans for detecting metastases. He highlights the potential of sestamibi scanning for identifying benign kidney conditions and the promising results from t...
|
- Details
- Pedro Barata and David Braun delve into the evolving landscape of biomarkers in renal cell carcinoma (RCC). Dr. Braun emphasizes the transition from histological analysis to advanced techniques like genomics and transcriptomics, highlighting their potential to differentiate between molecular subtypes of RCC and predict therapy responses. Specifically, transcriptomics could pave the way for tailore...
|
- Details
- Alicia Morgans interviews Toni Choueiri about the results of the KEYNOTE-564 trial, marking a significant milestone in kidney cancer treatment with pembrolizumab showing an overall survival benefit as an adjuvant therapy. Dr. Choueiri highlights the trial's inclusion criteria, focusing on patients at some risk of recurrence post-surgery with clear cell RCC. The study, which involved 17 cycles of p...
|
- Details
- Nirmish Singla presents research on socioeconomic determinants and racial disparities in renal cell carcinoma. Dr. Singla's study, published in Urologic Oncology, explores the complex interplay of biological, socioeconomic, and cultural factors influencing race-specific outcomes in healthcare. Focusing on African American and Caucasian patients with renal cell carcinoma, the study analyzes data fr...
|
- Details
- Zach Klaassen interviews Cristiane Bergerot to explore health-related quality of life (HRQoL) in renal cell carcinoma patients, with Bergerot asserting that existing measures often overlook relevant aspects. She elaborates on her study, examining patient's perceptions of common HRQoL measures like FKSI-19, EORTC QLQ-C30, and EQ-5D. Involving 147 participants from the US, Brazil, and Europe, the st...
|
- Details
- Kathryn Gessner discusses her focus on improving patient-centered communication for managing small renal masses, an issue faced by 30% of such patients. She explores how multiple management options, from surgical resection to active surveillance and cryoablation, can lead to decisional conflict for patients. Her work reveals that 20-30% of these masses are benign and carry a low risk of mortality...
|
- Details
- In this conversation, Pedro Barata and Ben Maughan discuss non-clear renal cell carcinoma (RCC) and the PAPMET study, which compared the efficacy of cabozantinib versus sunitinib in MET papillary RCC. The study found that cabozantinib significantly improved progression-free survival and became the standard of care for first-line therapy in papillary RCC. They also highlight the need for further st...
|
- Details
- Kosuke Tamekura joins Pedro Barata to discuss results from the International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) looking at outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies. Data from over 40 institutions worldwide is being collected to assess patients' demographics and outcomes. Patients with brain metastases from...
|
- Details
- Brian Shuch joins Pedro Barata to discuss the recent results from ZIRCON, a phase 3 study of 89 Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ccRCC). There is an unmet need for an accurate noninvasive method for pre-treatment risk stratification in detecting renal masses. The trial evaluated the efficacy of the imaging agent desferrioxamine-zirconium-girentuximab (Teli...
|
